Appling the Screws To the FDA
- FDA Green-lights New Type 2 Oral Med. Trecroci, D. // Diabetes Health;Dec2006/Jan2007, Vol. 15 Issue 12, p11
The article focuses on the approval of the oral medication Januvia by the U.S. Food and Drug Administration on October 17, 2006. Januvia is manufactured by Merck and Co. and is indicated for use in addition to diet to improve blood sugar levels in patients with type 2 diabetes. It cites the most...
- Molecule of the Month. Lindsley, Craig W. // Current Topics in Medicinal Chemistry;Nov2008, Vol. 8 Issue 17, p1553
The article reports on the decision of pharmaceutical companies to withdraw their application for U.S. Food and Drug Administration (FDA) approval of cannabinoid receptor (CB1) antagonist which is believed to be effective in treating obesity. Clinical trials have shown that the drug is linked to...
- First in DPP-4 inhibitor class cleared for diabetes. // Drug Topics;11/20/2006, Vol. 150 Issue 22, p18
The article reports on the U.S. Food and Drug Administration's approval of Merck & Co.'s sitagliptin, Januvia, as both a monotherapy and an add-on treatment to improve glycemic control in Type 2 diabetes. According to Merck, sitagliptin inhibits the action of dipeptidyl peptidase-4 and slows...
- Pharma: Other News To Note. // BioWorld Today;2/14/2012, Vol. 23 Issue 21, p8
the article reports on the approval of Zioptan (tatfluprost ophthalmic solution) from Merck & Co. Inc. by the U.S. Food and Drug Administration (FDA) for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Merck's Zioptan Joins Prostaglandin Market. // Review of Ophthalmology;Apr2012, Vol. 19 Issue 4, p114
The article reports that the use of Zioptan 0.0015%, an analog ophthalmic solution from Merck & Co. Inc., for reducing elevated intraocular pressure in individuals with ocular hypertension or open-angle glaucoma has been approved by the U.S. Food and Drug Administration (FDA).
- Merck Wins an Approval. // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p218
The article reports on the approval of Sylatron, a melanoma treatment from Merck & Co. Inc., by the U.S. Food and Drug Administration (FDA) in 2011.
- FDA wants cholesterol drug limits. Baker, Sam // Hill;6/13/2011, Vol. 18 Issue 83, p14
The article reports on the decision of the U.S. Food and Drug Administration (FDA) to limit the use of the highest dose of Zocor, a cholesterol drug from Merck & Co. Inc., because of alleged increased risks of muscle damage in 2011.
- Eye Pressure Medication Gets Approval From the FDA. // Chain Drug Review;3/26/2012, Vol. 34 Issue 6, p66
The article reports on the approval of several medications by the U.S. Food and Drug Administration including eye pressure remover Zioptan from Merck & Co. Inc., head lice remedy Sklice from Sanofi Pasteur SA and Avonex Pen injector for multiple sclerosis from Biogen Idec Inc.
- Merck Unit Gets Approval From the FDA For Zontivity. // Chain Drug Review;6/2/2014, Vol. 36 Issue 9, p49
The article reports that Merck, Sharp and Dome, a division of Merck and Co., has received the approval of the U.S. Food and Drug Administration (FDA) for its Zontivity (vorapaxar) drug used to reduce thrombotic cardiovascular events.